Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 318

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 318
---
 light of the number and wide variety of factors considered in connection with its evaluation of the proposed Business Combination, the NorthView Board did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. The NorthView Board contemplated its decision as in the context of all of the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. This explanation of NorthView’s reasons for approving the Business Combination and all other information presented in this section is forward -lookingin nature and, therefore, should be read in light of the factors discussed under the section titled “ Cautionary Note Regarding Forward -Looking Statements.” In approving the Business Combination, the NorthView Board decided to obtain a fairness opinion. The officers and directors of NorthView have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries but specifically focusing on the healthcare industry and concluded that their experience and background, together with the experience of their advisors including Marshall & Stevens, enabled them to make the necessary analyses and determinations regarding the Merger. The NorthView Board considered a number of factors pertaining to the Business Combination as generally supporting its decision to enter into the Merger Agreement and the transactions contemplated thereby, including, but not limited to, the following: (i)Late -stagedevelopment or revenue generating (ii)High growth prospects with sustainable proprietary position (iii)Experienced management teams with previous successes, especially where we can add critical public company expertise (iv)Addressable conditions that are clinically important and under -diagnosedor treated (v)Independent companies or corporate spin offs (vi)Domestic or International base of business 160 Profusa meets many of the criteria listed above, including its ability to generate revenue from the Lumee Oxygen product in Europe without further regulatory approval and the potential to generate revenue from Lumee Oxygen product in the U.S. and the Lumee Glucose product in both Europe and the U.S. following regulatory approval, its growth plan to be a leading digital health technology company, its experienced management team, its clinically important consumer -friendlyplatform, its private independent structure, and its potential domestic and international base of business. More specifically, the NorthView Board took into consideration the following factors or made the following determinations, as applicable: (i) A target company in the health care sector with near term revenue potential: Profusa’s biosensor technology